难治性高血压三种肾去交感神经术式头对头随机试验
RADIOSOUND-HTN 将 120 例难治性高血压患者按 1:1:1 随机分配至主肾动脉射频消融、主肾动脉加分支射频消融或主肾动脉血管内超声消融三组,主要终点为 3 个月日间收缩压动态血压变化。全队列 3 个月日间收缩压下降 9.5±12.3 mmHg(P<0.001),超声组降幅显著大于主肾动脉射频组(-13.2±13.7 对 -6.5±10.3 mmHg,平均差 -6.7 mmHg,校正 P=0.043)。
要点
- 血管内超声肾去交感神经术降压幅度优于单纯主肾动脉射频消融。
- 主肾动脉加分支射频消融与单纯主肾动脉射频消融降压无显著差异。
- 三组血压反应率(下降≥5 mmHg)无显著差异(整体 P=0.77)。
核心结论
- 在难治性高血压患者中,血管内超声肾去交感神经术优于单纯主肾动脉射频消融,而主肾动脉加分支射频联合消融未显示优势。
研究设计与样本
- 三臂随机对照试验,2015 年 6 月至 2018 年 6 月共纳入 120 例难治性高血压患者,按 1:1:1 随机分配。
- 三组分别接受主肾动脉射频消融(39 例)、主肾动脉加分支射频消融(39 例)或主肾动脉血管内超声消融(42 例)。
- 主要终点为 3 个月日间收缩压动态血压变化。
主要发现
- 全队列 3 个月日间收缩压下降 9.5±12.3 mmHg(P<0.001)。
- 超声组日间收缩压下降 -13.2±13.7 mmHg,主肾动脉射频组下降 -6.5±10.3 mmHg,平均差 -6.7 mmHg(整体 ANOVA P=0.038,校正 P=0.043)。
- 主肾动脉加分支射频组下降 -8.3±11.7 mmHg,与主肾动脉射频组平均差 -1.8 mmHg(校正 P>0.99)。
- 超声组与加分支射频组降压幅度无显著差异。
- 三组血压反应率(下降≥5 mmHg)无显著差异(整体 P=0.77)。
关键数值与推荐
- 难治性高血压患者基线平均日间血压 153/86±12/13 mmHg,平均年龄 64±9 岁。
- 主要终点为 3 个月日间收缩压动态血压变化。
- 血压反应定义为下降≥5 mmHg。
临床怎么用
- 难治性高血压行肾去交感神经术时可优先考虑血管内超声消融,其降压幅度优于单纯主肾动脉射频消融。
- 主肾动脉加分支射频消融未较单纯主肾动脉射频消融进一步改善 3 个月降压效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both radiofrequency and ultrasound endovascular renal sympathetic denervation (RDN) have proven clinical efficacy for the treatment of hypertension. We performed a head-to-head comparison of these technologies. METHODS: Patients with resistant hypertension were randomly assigned in a 1:1:1 manner to receive either treatment with (1) radiofrequency RDN of the main renal arteries; (2) radiofrequency RDN of the main renal arteries, side branches, and accessories; or (3) an endovascular ultrasound-based RDN of the main renal artery. The primary end point was change in systolic daytime ambulatory blood pressure at 3 months. RESULTS: Between June 2015 and June 2018, 120 patients were enrolled (mean age, 64±9 years±SD; mean daytime blood pressure, 153/86±12/13 mm Hg). Of these, 39 were randomly assigned to radiofrequency main renal artery ablation, 39 to combined radiofrequency ablation of the main artery and branches, and 42 to ultrasound-based treatment. Baseline daytime blood pressure, clinical characteristics, and treatment were well balanced between the groups. At 3 months, systolic daytime ambulatory blood pressure decreased by 9.5±12.3 mm Hg ( P<0.001) in the whole cohort. Although blood pressure was significantly more reduced in the ultrasound ablation group than in the radiofrequency ablation group of the main renal artery (-13.2±13.7 versus -6.5±10.3 mm Hg; mean difference, -6.7 mm Hg; global P=0.038 by ANOVA, adjusted P=0.043), no significant difference was found between the radiofrequency ablation groups (-8.3±11.7 mm Hg for additional side branch ablation; mean difference, -1.8 mm Hg; adjusted P>0.99). Similarly, the blood pressure reduction was not found to be significantly different between the ultrasound and the side branch ablation groups. Frequencies of blood pressure response ≥5 mm Hg were not significantly different (global P=0.77). CONCLUSIONS: In patients with resistant hypertension, endovascular ultrasound-based RDN was found to be superior to radiofrequency ablation of the main renal arteries only, whereas a combined approach of radiofrequency ablation of the main arteries, accessories, and side branches was not. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02920034.
引用
- Fengler K, Rommel KP, Blazek S, et al. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN). Circulation. 2019. PMID: 30586691. doi:10.1161/CIRCULATIONAHA.118.037654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。